Company Overview and News

1
Composite Scheme of Arrangement (Demerger) of Oudh Sugar Mills Ltd.

2017-03-22 indiainfoline
Trading Members of the Exchange are hereby informed that, pursuant to the Composite Scheme of Arrangement (Demerger) approved by the Hon’ble National Company Law Tribunal, Allahabad, Oudh Sugar Mills Ltd., has fixed the Record Date for the purpose of determining entitlement of the shareholders of the Company, as per details given below:

 
The Oudh Sugar Mills Limited - Record Date

2017-03-15 feedproxy.google

 
The Oudh Sugar Mills Limited - Others

2017-03-10 feedproxy.google

 
 
Market rises for 4th straight session

2017-02-06 indiainfoline
Trading for the week started on a firm footing as key benchmark indices settled with decent gains. The barometer index, the S&P BSE Sensex, rose 198.76 points or 0.70% to settle at 28,439.28. The Nifty 50 index rose 60.10 points or 0.69% to settle at 8,801.05. The Sensex and the Nifty, both, hit their highest closing level in 4-1/2-months.

 
Oudh Sugar Mills gets upgradation in ratings for bank facilities

2017-01-03 indiainfoline
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

 
 
Sweet tidings: sugar scrips soar as prices rise in commodities market

2016-12-23 thehindubusinessline
Shares of sugar companies climbed sharply on Friday, thanks to a rebound in raw sugar prices in the global commodities market.

 
Key indices hover in narrow range

2016-12-06 indiainfoline
Key benchmark indices were range bound in afternoon trade. At 13:16 IST, the barometer index, the S&P BSE Sensex, was up 105.79 points or 0.40% at 26,454.89. The Nifty 50 index was up 34.20 points or 0.42% at 8,162.95. Positive leads from Asian markets and overnight rally on the Wall Street boosted investors sentiment in the domestic market.

 

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...